Literature DB >> 21298435

Effects of immunoadsorption on endothelial function, circulating endothelial progenitor cells and circulating microparticles in patients with inflammatory dilated cardiomyopathy.

Daniel Bulut1, Michael Scheeler, Lisa Marie Niedballa, Thomas Miebach, Andreas Mügge.   

Abstract

BACKGROUND: Immunoadsorption (IA) is used in patients with chronic inflammatory dilative cardiomyopathy (iDCM) to remove cardiotoxic autoantibodies, and to improve myocardial function. We examined the effects of IA on endothelial function, circulating endothelial progenitor cells, and circulating microparticles, including endothelial-derived microparticles, in patients with chronic iDCM.
METHODS: Thirteen patients (10 males, 3 females, mean age 52.3 years) with advanced congestive heart failure (NYHA III and IV) secondary due to chronic iDCM (with signs of myocardial inflammation in biopsies, but without persistence of virus genome), and reduced left ventricular ejection fraction (EF < 35%) underwent IA. Blood samples were drawn before an IA course of 5 days, and 6 months after IA. Blood levels of endothelial progenitor cells (EPCs as defined as VEGFR2(+)CD34(+) cells), of microparticles (MPs as defined as Annexin V(+) particles with a diameter between 0.1 and 1 μm), and of endothelial-derived MPs (eMPs as defined as CD31(+bright) CD42b(-)/Annexin V(+) particles) were analyzed by flow cytometry. Endothelial function (expressed as reactive hyperemia index (RHI)) and arterial stiffness were assessed by PAT-technology (peripheral arterial tone) using fingertips.
RESULTS: Left ventricular systolic function (EF%) improved on average at 6 months from 26.3 ± 4.8 to 37.9 ± 9.6% (mean ± SEM; p < 0.05). The LV end-diastolic diameter reduced after 6 months from 68.4 ± 8.2 to 61.6 ± 7.9 mm; p < 0.05). Endothelial function improved from 1.53 ± 0.09 to 1.80 ± 0.12 (p < 0.05). The arterial stiffness index remained unchanged. Number of total MPs decreased on average by 36.8% (p < 0.05), the number of eMPs by 39.6% (p < 0.05), respectively. The level of circulating EPC remained unchanged (EPC/PMNC 0.26 ± 0.07 vs. 0.27 ± 0.05 ‰, p = n.s.).
CONCLUSIONS: IA treatment improves endothelial function in patients with chronic iDCM. This effect is associated with a significant drop in circulating microparticles. The causal relationship between circulating microparticles and endothelial function is discussed.

Entities:  

Mesh:

Year:  2011        PMID: 21298435     DOI: 10.1007/s00392-011-0287-2

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  51 in total

Review 1.  Flow cytometric analysis of circulating microparticles in plasma.

Authors:  Aaron F Orozco; Dorothy E Lewis
Journal:  Cytometry A       Date:  2010-06       Impact factor: 4.355

2.  Immunoadsorption in idiopathic dilated cardiomyopathy, a 3-year follow-up.

Authors:  Wolf V Dörffel; Gerd Wallukat; Yvonnne Dörffel; Stephan B Felix; Gert Baumann
Journal:  Int J Cardiol       Date:  2004-12       Impact factor: 4.164

Review 3.  Microparticles as mediators of cellular cross-talk in inflammatory disease.

Authors:  Jörg H W Distler; Lars C Huber; Steffen Gay; Oliver Distler; David S Pisetsky
Journal:  Autoimmunity       Date:  2006-12       Impact factor: 2.815

4.  Hormonal status modulates circulating endothelial progenitor cells.

Authors:  Daniel Bulut; Nadine Albrecht; Matthias Imöhl; Bülent Günesdogan; Nadine Bulut-Streich; Jan Börgel; Christoph Hanefeld; Michael Krieg; Andreas Mügge
Journal:  Clin Res Cardiol       Date:  2007-02-26       Impact factor: 5.460

5.  Endothelial pulse amplitude testing: feasibility and reproducibility in adolescents.

Authors:  Elif Seda Selamet Tierney; Jane W Newburger; Kimberlee Gauvreau; Judith Geva; Elizabeth Coogan; Steven D Colan; Sarah D de Ferranti
Journal:  J Pediatr       Date:  2009-02-12       Impact factor: 4.406

6.  Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure.

Authors:  Stuart D Katz; Katarzyna Hryniewicz; Ingrid Hriljac; Kujtim Balidemaj; Clarito Dimayuga; Alhakam Hudaihed; Aleksandr Yasskiy
Journal:  Circulation       Date:  2005-01-17       Impact factor: 29.690

7.  Effect of protein A immunoadsorption on T cell activation in patients with inflammatory dilated cardiomyopathy.

Authors:  Daniel Bulut; Michael Scheeler; Tim Wichmann; Jan Börgel; Thomas Miebach; Andreas Mügge
Journal:  Clin Res Cardiol       Date:  2010-04-25       Impact factor: 5.460

8.  Effects of protein A immunoadsorption in patients with advanced chronic dilated cardiomyopathy.

Authors:  Andreas O Doesch; Mathias Konstandin; Sultan Celik; Arnt Kristen; Lutz Frankenstein; Stefan Hardt; Stefan Goeser; Ziya Kaya; Hugo A Katus; Thomas J Dengler
Journal:  J Clin Apher       Date:  2009       Impact factor: 2.821

Review 9.  Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance.

Authors:  Alida L P Caforio; Niall J Mahon; Francesco Tona; William J McKenna
Journal:  Eur J Heart Fail       Date:  2002-08       Impact factor: 15.534

10.  CD31+/Annexin V+ microparticles in healthy offsprings of patients with coronary artery disease.

Authors:  D Bulut; H Tüns; A Mügge
Journal:  Eur J Clin Invest       Date:  2009-01       Impact factor: 4.686

View more
  7 in total

1.  First in vitro and in vivo results of an anti-human CD133-antibody coated coronary stent in the porcine model.

Authors:  Alexander Sedaghat; Jan-Malte Sinning; Kathrin Paul; Gregor Kirfel; Georg Nickenig; Nikos Werner
Journal:  Clin Res Cardiol       Date:  2013-02-10       Impact factor: 5.460

2.  Chronic protection against ischemia and reperfusion-induced endothelial dysfunction during therapy with different organic nitrates.

Authors:  Monica Lisi; Matthias Oelze; Saverio Dragoni; Andrew Liuni; Sebastian Steven; Mary-Clare Luca; Dirk Stalleicken; Thomas Münzel; Franco Laghi-Pasini; Andreas Daiber; John D Parker; Tommaso Gori
Journal:  Clin Res Cardiol       Date:  2012-06       Impact factor: 5.460

3.  Long-term outcome of patients with virus-negative chronic myocarditis or inflammatory cardiomyopathy after immunosuppressive therapy.

Authors:  Felicitas Escher; Uwe Kühl; Dirk Lassner; Wolfgang Poller; Dirk Westermann; Burkert Pieske; Carsten Tschöpe; Heinz-Peter Schultheiss
Journal:  Clin Res Cardiol       Date:  2016-06-16       Impact factor: 5.460

Review 4.  Microvesicles as Emerging Biomarkers and Therapeutic Targets in Cardiometabolic Diseases.

Authors:  Yan Chen; Guangping Li; Ming-Lin Liu
Journal:  Genomics Proteomics Bioinformatics       Date:  2018-02-17       Impact factor: 7.691

5.  Archaea Symbiont of T. cruzi Infection May Explain Heart Failure in Chagas Disease.

Authors:  Maria de Lourdes Higuchi; Joyce T Kawakami; Renata N Ikegami; Marcia M Reis; Jaqueline de Jesus Pereira; Barbara M Ianni; Paula Buck; Luanda Mara da Silva Oliveira; Marilia H H Santos; Ludhmila A Hajjar; Edimar A Bocchi
Journal:  Front Cell Infect Microbiol       Date:  2018-11-21       Impact factor: 5.293

6.  Changes of myocardial gene expression and protein composition in patients with dilated cardiomyopathy after immunoadsorption with subsequent immunoglobulin substitution.

Authors:  Sabine Ameling; Gourav Bhardwaj; Elke Hammer; Daniel Beug; Leif Steil; Yvonne Reinke; Kerstin Weitmann; Markus Grube; Christiane Trimpert; Karin Klingel; Reinhard Kandolf; Wolfgang Hoffmann; Matthias Nauck; Marcus Dörr; Klaus Empen; Stephan B Felix; Uwe Völker
Journal:  Basic Res Cardiol       Date:  2016-07-13       Impact factor: 17.165

7.  Myocardial gene expression profiles and cardiodepressant autoantibodies predict response of patients with dilated cardiomyopathy to immunoadsorption therapy.

Authors:  Sabine Ameling; Lars R Herda; Elke Hammer; Leif Steil; Alexander Teumer; Christiane Trimpert; Marcus Dörr; Heyo K Kroemer; Karin Klingel; Reinhard Kandolf; Uwe Völker; Stephan B Felix
Journal:  Eur Heart J       Date:  2012-10-25       Impact factor: 29.983

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.